secwatch / observer

8-K filed March 30, 2023, 7:59 PM ET ticker GALT CIK 0001133416

earnings confidence high sentiment neutral materiality 0.60

Galectin Therapeutics reports 2022 net loss of $38.9M; NAVIGATE trial on track

GALECTIN THERAPEUTICS INC

Net loss $38.9M ($0.65/share) vs $30.7M ($0.52) in 2021.
R&D expenses $31.7M, up from $23.8M, driven by NAVIGATE trial costs.
Cash $18.6M; $50M credit line available; expects funding through Dec 2024.
NAVIGATE trial randomized 357 patients; DSMB positive; interim results Q4 2024.
Evaluating Phase 2 trial of belapectin + Keytruda for head and neck cancers.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

GALECTIN THERAPEUTICS INC reported the year ended December 31, 2022 results: net income $38.9 million, EPS ($0.65) per share.

Period: the year ended December 31, 2022
Net income: $38.9 million
EPS: ($0.65) per share
Result: reported results

Exact text from the filing

For the year ended December 31, 2022, the Company reported a net loss applicable to common stockholders of $38.9 million, or ($0.65) per share

View on SEC.gov

Browse all earnings releases →

GALECTIN THERAPEUTICS INC filing history →

Source: SEC EDGAR

accession 0001140361-23-014660

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.